gogogoo 22 september 2006 12:04 auteur info gogogoo Lid sinds: 28 feb 2006 Laatste bezoek: 10 aug 2023 Aanbevelingen Ontvangen: 1600 Gegeven: 808 Aantal posts: 6.042 Dutch firms to join Cambridge biotech clusterBy Jeffrey Krasner, Globe Staff | September 22, 2006A joint biotechnology research venture by two Dutch companies is further underscoring the appeal of the Boston life-science cluster to out-of-state firms, and creating an even tighter real estate market in Cambridge's Kendall Square.Breaking News Alerts The companies, Crucell N.V. and Royal DSM N.V., decided to lease buildings at 1 Hampshire St. after considering locations in Maryland and the Research Triangle Park in North Carolina, according to Dr. Marco Cacciuttolo, chief executive of the joint venture.``Cambridge is the real gravitational center of biotechnology," said Cacciuttolo. ``It's really the premier location in the world to engage in these research activities."The facility will employ about 50 people when fully staffed, he said.In recent years, companies including Schering-Plough Corp., Akzo Nobel N.V., Novartis Pharma, and Merck & Co. Inc. have set up substantial research operations in Boston or Cambridge. They seek access to top biopharmaceutical talent; cutting-edge research from Harvard University, the Massachusetts Institute of Technology, and other schools; and the intangible advantage that comes from being surrounded by other life-science businesses.The action isn't just limited to the Boston-Cambridge area. In June, drug giant Bristol-Myers Squibb Co. said it would build a $660 million manufacturing plant on part of the site of the former Fort Devens in central Massachusetts.The Crucell-Royal DSM venture is called PER.C6 Development Center LLC, after a specific line of human cells that the companies are developing.Many biotechnology companies manufacture treatments by modifying the genetic instructions in animal cells so they produce a specific protein with therapeutic properties. Often, those therapeutics are grown in cells derived from hamster ovaries.But scientists have found that using proteins made from animal cells can cause dangerous side effects. They have attempted to make the therapeutics more ``human," with fewer characteristics of the host cell.PER.C6 has developed a line of cells it believes will eliminate problems associated with proteins made from animal cells and plans to license the line to biotech companies.``We want to license the cell line to everybody," said Cacciuttolo.The venture is equally funded by the two partners. Crucell makes vaccines for two types of hepatitis, influenza, and the diseases that plague travelers, including typhoid. DSM is a sprawling enterprise that manufactures food and pharmaceutical ingredients, and chemicals for a wide variety of applications. It has 22,000 employees and annual sales of about $10 billion. Its biologics division provides manufacturing services to biotech companies.The new venture will occupy most of the remaining space in a complex of new and existing buildings owned by Draper Laboratory. Last year Schlumberger Technology Corp. leased 190,000 square feet in the complex.PER.C6 R&D Center is believed to be paying annual rent between $55 and $60 per square foot, and will also contribute to utility costs, real estate taxes, and building operating expenses, according to real estate brokers familiar with East Cambridge. It will receive an allowance of more than $100 per square foot from Draper to convert the bare space into laboratories and offices.``The biotech cluster is a powerful draw," said Ryan Weber , a life-science specialist with NAI Hunneman Commercial , a real estate firm that represented PER.C6. ``This group felt they needed to be in Kendall Square."Just two years ago, there was a 26.2 percent vacancy rate in Cambridge laboratory and research-and-development space, according to Mark J. Winters , executive director of Cushman & Wakefield of Massachusetts Inc., a real estate firm that represented Draper Laboratory. In the second quarter of this year, the vacancy rate dropped to 11.5 percent. Excluding space available through subleasing, the rate was even lower, 5.5 percent.``The lab market has shifted from a tenant to a landlord market in a very short period of time," said Winter s .Posted by Author: ron bangedwww1.investorvillage.com/smbd.asp?mb=... Aanbevelingen 25 ” Quote Reageren Niet oké
[verwijderd] 22 september 2006 12:18 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Gogogo, dank voor deze posting!Dit klinkt toch prachtig:PER.C6 Development Center LLC, Cambridge USAEn ze zijn er maar wat blij mee daar in de Boston area! Er ontstaat nu zelfs schaarste op de laboratorium/ kantorenmarkt. Crucell/DSM waren er nog net op tijd bij!!Grtz,ZEKER Aanbevelingen 1 ” Quote Reageren Niet oké
gogogoo 22 september 2006 12:19 auteur info gogogoo Lid sinds: 28 feb 2006 Laatste bezoek: 10 aug 2023 Aanbevelingen Ontvangen: 1600 Gegeven: 808 Aantal posts: 6.042 ``We want to license the cell line to everybody," said Cacciuttolo. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 september 2006 20:04 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Om je vingers bij af te likken gogogoo , ab!Nog een stuk of tig AB's...en hop, op de voorpagina...we blijven werken voor onze centjes. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 september 2006 20:12 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:flosz schreef:Om je vingers bij af te likken gogogoo , ab!Nog een stuk of tig AB's...en hop, op de voorpagina...we blijven werken voor onze centjes.Ok Flosz,Dit prachtige bericht moet zeker op de voorpagina maar niet meer dan 22 x.Waarom dan niet, omdat ik nog steeds wel een beetje trots ben op mijn positie van meest aanbevolen bericht.Voelde jij dit ook zo de eerste keer......groet,Truco Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 september 2006 20:21 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:truco1 schreef:Voelde jij dit ook zo de eerste keer......Uh nee, sorry....maar lang geleden, toen ik nog heel klein was, was ik erg blij met de plaatsing van een art.-je in de........schoolkrant!gr. Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.